Paper Alert: DIAN Biomarker Data Show Changes Decades Before AD
Data from the DIAN paint a sobering picture, showing that a cascade of pathophysiological changes begins decades before a person is likely to develop familial AD...
ALL NEWS
463 RESULTS
Sort By:
- Most Recent
- Most Commented
Communication Breakdown: Multiple Networks Decline in AD Brains
A healthy brain switches between its different functional networks like a well-oiled machine, but as dementia takes over, communication becomes disorganized...
Toward FTD Therapeutic Trials: Diagnosis Firm, Outcomes Still Soft
Scientists from academia, industry, and funding organizations met to discuss precompetitive steps in the preparation for clinical trials for frontotemporal degeneration...
What’s Sex Got to Do With It? Differences in Connectivity, Synapses
Women run a higher risk of getting Alzheimer’s disease than do men, yet surprisingly little is known about how gender interacts with the disease or affects the brain...
Optimizing CSF Aβ42 ELISA for Trials and Regulatory Approval
Testing a widely used cerebrospinal fluid Aβ42 immunoassay, scientists proposed modifications that they believe improve its precision and accuracy...
DIAN Grows, Gets Ready for Therapeutic Trials
The Dominantly Inherited Alzheimer Network Pharma Consortium met in Washington, D.C., to exchange the latest information on DIAN’s preparation for therapeutic trials...
Keystone: Diagnosis and Model Treatments for Traumatic Brain Injury
Identifying injuries that might lead to chronic traumatic encephalopathy or other neurodegenerative pathologies, and then treating those injuries, are two major challenges...
Keystone: TBI—Learning From Markers, Models, and Diseases
Injury to the brain, even what might be considered mild, can have devastating consequences on brain physiology...
Biomarker Duo Signals Mental Decline
Increasingly, upcoming trials for Alzheimer's therapeutics will target prevention—seeing whether drugs can stave off the disease before it takes hold...
Research Brief: Bead-Based Biomarkers Neatly Divide AD, FTLD
The total tau to amyloid-β42 ratio from cerebrospinal fluid reliably distinguishes Alzheimer’s disease from frontotemporal degeneration...
Plasma Aβ as Biomarker: Not a Lost Cause, After All?
Researchers have been measuring Aβ for decades, trying to nail down its behavior in Alzheimer's patients or those nearing the disease...
Antioxidants No Help for Alzheimer’s, Biomarker Trial Says
The stuff touted to confer anti-aging properties on foods from blueberries to dark chocolate does no good for people with Alzheimer’s disease—and might even make them worse...
Research Brief: VILIP-1 a Potential CSF Marker for AD?
Continued setbacks in Alzheimer’s disease clinical trials have fueled a sense that candidate drugs have been tested in patients whose disease has already progressed too far...
Brain Proteins in Flux a Decade Before Familial AD Begins
Move over Aβ and tau; it turns out that dozens of proteins rise and fall in the CSF of familial AD mutation carriers a decade before onset of the disease...
Research Brief: More Evidence That CSF Aβ Changes Precede AD
The longest study yet to correlate AD biomarkers in CSF with disease progression confirms that β amyloid levels bottom out up to 10 years before the clinical onset of disease...